

**INVESTIGATIONS INTO THE UTILITY OF
REAL-TIME PCR FOR THE DETECTION,
QUANTITATION AND CHARACTERISATION
OF CLINICALLY RELEVANT VIRUSES.**

Ian M. Mackay B.App.Sci (MScQual)

A thesis submitted to the University of Queensland in fulfillment of the requirements for the degree of Doctor of Philosophy.

School of Medicine
Central Clinical Division
University of Queensland
St. Lucia, Queensland

DECLARATION

Except where due reference is cited in the text, this thesis is the original work of the author. No part of the original studies from this thesis has been submitted, in any form, to this or any other University.

Ian Maxwell Mackay

___ / ___ / ___

ABSTRACT

The use of PCR as a tool for the diagnostic virology and viral research laboratories has greatly increased in recent years, however the use of conventional PCR and amplicon detection systems can be a complex and relatively slow process that increases the risk of amplicon carry-over contamination. Many conventional PCR systems are unsuited for, or unable to perform as accurate diagnostic and quantitative tools because viruses are present in such a diverse variety of patient tissues and in a broad range of concentrations. Traditional viral culture, while still the gold standard for the detection of many viruses, is lengthy, expensive and often subjective. In addition, successful isolation of infectious virus is variable and dependent upon appropriate cell lines, lengthy incubations and careful transport and storage of clinical specimens. Many of the disadvantages arising from the use of traditional assays for the detection of viruses have been overcome by the development of real-time PCR. The technology has continued to develop due to the introduction of several commercial thermal cycling platforms and the appearance of numerous specific and non-specific fluorogenic chemistries.

For the purpose of this thesis, human virology was sectioned into three diagnostic divisions containing the synthetic viruses, the well characterised viruses and the new or emerging viruses. This thesis

proposes the hypothesis that real-time PCR could greatly improve upon traditional techniques for the detection, quantitation and characterisation of the members of these three divisions in both research and diagnostic environments.

Conventional competitive quantitative PCR assays and a non-oligoprobe real-time PCR assay were constructed to detect novel synthetic gene therapy vectors developed from retroviruses. When compared to oligoprobe-based real-time PCR, it was clear that conventional molecular assays, whilst improving upon traditional methods of viral culture and immunofluorescence, were slower, more complex, less versatile and were hindered by a limited dynamic range. Synthetic control templates were developed and an improved method of assaying these template preparations was devised. The controls were used to precisely optimise each assay, create quality assurance reagents and to construct external standard curves permitting the absolute quantitation of viral templates.

Real-time PCR achieved several significant goals during the studies performed for this thesis. The new assays detected human enterovirus (HEV) and the emerging pathogen, human metapneumovirus (hMPV) which were both responsible for seasonal outbreaks of serious disease that would otherwise have gone undiagnosed. These data led to the first description of hMPV outside

of the Netherlands, as well as the first description of two validated rapid diagnostic RT-PCR assays which permitted the definitive classification of hMPV as a global pathogen of children and adults. Building upon its detection, an extensive molecular epidemiological study permitted the description of subtle differences between Australian and the more recently described international hMPV strains resulting in the classification of two distinct types of hMPV (A and B) and within these, four subtypes (A1, A2, B1 and B2).

Real-time PCR rapidly detected, quantitated and genotyped herpes simplex viruses in a single reaction and determined the successful delivery of human and non-human genes by novel retroviral vectors in less time than any other phenotype detection assay. Additionally, these studies produced quantitative data which permitted the rapid calculation of transduction efficiency. Real-time PCR was able to quickly assess the efficiency of the PCR either in response to the titration of individual reaction components or as a result of amplification modifiers present within specimen extracts. The use of nucleotide sequencing studies ideally complemented earlier diagnostic studies of HEV and permitted the discrimination of pathogenic enterovirus 71.

This thesis demonstrated that real-time PCR is more able to accommodate the demanding aspects of viral research and

diagnostics than any other single method, and is now in a position to replace many of the traditional techniques still used by laboratories unfamiliar with the benefits of real-time PCR. The assays, techniques, reagents and publications resulting from these studies have benefited several areas of viral research and diagnostics and have improved the understanding of the role of real-time PCR in virology and of the technique in general, among the greater scientific community whilst successfully addressing the proposed hypothesis.

ACKNOWLEDGMENTS

Dr. John Pope for your leadership and for giving me the opportunity to study and work at a young and enthusiastic SASVRC.

Professor Eric Gowans and Dr. Ming Wei for their contribution to the strengthening of my character.

Professor Ed. Westaway, a remarkable reservoir of knowledge and a friend to students in need.

The many quality students, scientists and support staff I have befriended during my time at SASVRC. May you all progress to bigger and better things and strive to make a difference.

Dr. Michael Nissen for the clinical expertise, the boundless enthusiasm, and the willingness to accommodate a new student.

Boris, David and Mello - an Unreal trio of network specialists with too many redeeming qualities to list.

Kevin, you have been a pleasure to work with and to guide. Now its your turn.

Andreas, a friend of the thesis – a rare treasure.

Theo, your extraordinarily level-headed outlook and friendship was greatly appreciated.

Anakin – if only you had thumbs.

My Mother – for always being so proud of me.

Most importantly I thank my wife, my friend and my heart, Katherine.

Without you life would be grey.....and full of commas. ILYA.

ABBREVIATIONS

aa	Amino acid
APV	Avian pneumovirus
AR	Analytical reagent grade
BHQ	Black hole quencher
bRSV	Bovine respiratory syncytial virus
CCD	Charge-coupled device
<i>Cftr</i> (CFTR)	Cystic fibrosis transmembrane conductance regulator gene (protein)
C_T	Threshold cycle
C_p	Crossing point
CVRU	Clinical Virology Research Unit
DABCYL	4-[4'-dimethylamino-phenylazo]-benzene
DIG	Digoxigenin
dNTP	deoxyribonucleotides
dsDNA	Double-stranded DNA
ELAHA	Enzyme linked amplicon hybridisation assay
ERV	Endogenous retrovirus
EV71	Enterovirus 71
FAM	6-carboxy-fluorescein
FCS	Foetal calf serum
FITC	Fluorescein isothiocyanate
FMCA	Fluorescence melting curve analysis.
FRET	Fluorescent resonance energy transfer
<i>Gfp</i> (GFP)	Green fluorescent protein gene (protein)
HEV	Human enteroviruses
hMPV	Human metapneumovirus
hRSV	Human respiratory syncytial virus
IC	Internal control
LB	Luria Bertani medium
LTR	Long terminal repeat
LUX	Light-up upon extension
MGB	Minor groove binding molecule
MHC	Major histocompatibility complex
MOI	Moiety of infection.
MoMLV	Moloney murine leukaemia virus

MQAE	<i>N</i> -(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide
mRNA	Messenger RNA
MSV	Murine Sarcoma Virus
NDV	Newcastle disease virus
NFQ	Non-fluorescent quencher
NTR	Non-translated region
ORF	Open reading frame
bRSV	Bovine respiratory syncytial virus
oRSV	Ovine respiratory syncytial virus
PCR	Polymerase chain reaction
PIV	Parainfluenza virus
PNA	Peptide nucleic acid
Poly(A)	Polyadenylated
PVM	Pneumonia virus of mice
qcPCR	Quantitative competitive PCR
QHPS	Queensland Health Pathology Service
RCH	Royal Children's Hospital
RCR	Replication competent retrovirus
rRNA	Ribosomal RNA
ROX	6-carboxy- <i>N,N,N',N'</i> -tetramethylrhodamine
RT	Reverse transcription
RT-PCR	Reverse transcription PCR
SASVRC	Sir Albert Sakzewski Virus Research Centre
SNP	Single nucleotide polymorphisms
SV	Simian virus
TAMRA	6-carboxy-tetramethyl-rhodamine
Taq	<i>Thermus aquaticus</i>
TCID ₅₀	50% Tissue culture infective dose
T _D	Denaturation temperature
T _M	Melting temperature
TMB	Tetramethylbenzidine
TRTV	Turkey rhinotracheitis virus
TV	Trypsin-versene solution
UTR	Untranslated region
VSV	Vesicular stomatitis virus

PUBLICATIONS

Mackay,IM, Metharom,P, Sloots,TP, Wei,MQ. (2001). Quantitative PCR-ELAHA for the determination of retroviral vector transduction efficiency. *Mol.Ther.* **3**;5, 801-807.

Whiley,DM, Mackay,IM, Sloots,TP. (2001). Detection and differentiation of human polyomavirus JC and BK by LightCycler PCR. *J.Clin.Microbiol.* **39**;12. 4357-4361.

Nissen,MD, Mackay,IM, Siebert,DJ, Withers,SJ, Sloots,TP. (2002). Evidence of human metapneumovirus in Australian children. *Med.J.Aust.* **176**. 188.

Mackay,IM, Arden,KE, Nitsche,A. (2002). Real-time PCR in virology. *Nuc.Acids.Res.* **30**;6. 1292-1305.

Whiley,DW, LeCornec,GM, Mackay,IM, Siebert,DJ, Sloots,TP. (2002). A real-time PCR assay for the detection of *Neisseria gonorrhoeae* by LightCycler. *Diag.Micro.Inf.Dis.* **42**, 85-89.

Whiley,DM, Syrmis,MW, Mackay,IM, Sloots,TP. (2002). Detection of human respiratory syncytial virus in respiratory samples by

LightCycler reverse transcriptase PCR. J.Clin.Microbiol. **40**, 4418-4422.

Mackay,IM, Jacob,KC, Woolhouse,D, Waller,K, Sirmis,MW, Whiley,DM, Siebert,DJ, Nissen,MN, Sloots,TP. (2003). Molecular assays for the detection of human metapneumovirus. J.Clin.Microbiol. **41**, 100-105.

Mackay,IM, Gardam,T, Arden,KE, McHardy,S, Whiley,DW, Sloots,TP. (2003). Co-Detection and Discrimination of Six Human Herpesviruses by Multiplex PCR-ELAHA. J.Clin.Virol. Accepted Jan 2003.

Mackay,IM. Real Time PCR in the clinical microbiology laboratory. Clin.Microbiol.Inf. Accepted Jan 2003.

PRESENTATIONS.

Slouts, TP., Mackay, IM*, Carton, T. (1998). Rapid and Sensitive Detection of Human Enterovirus Infections by Single-Tube RT-PCR. Australian Society for Microbiology, Oral.

Mackay, IM. (1998) Rapid and Sensitive Detection of Human Enterovirus Infections by Single-Tube RT-PCR. ASM Serology/Virology Special Interest Group. Oral.

Mackay, IM., Arden, KE., Williamson,J., Slouts,TP. (1999) Development and Evaluation of a Quantitative PCR for the Determination of Cytomegalovirus Load. XIth International Congress of Virology, Sydney. Abs:VP65.23.

Mackay, IM., Metharom,P., Wei,M. (1999) Quantitative RT-PCR for the Titration of Retroviral Vector Harvests. XIth International Congress of Virology, Sydney. Abs:VP65.23.

Mackay, IM. (May 2000). RCH Quality Networking Group interactive presentation on the Internet and Virology Down Under. (Oral)

Mackay, IM. (August 2000). Molecular Biology Special Interest Group, Aspects of Quantitative PCR. (Oral).

Mackay, IM., Nissen, M., Siebert, DP., Sloots, TP. (October 2001). Queensland Health and Medical Scientific Meeting. Brisbane, Australia. First Isolations Of Human Metapneumovirus In Australia. (Poster).

Mackay, IM., Crisante, E., Sloots, TP. (December 2001). Herston Campus Health Care Symposium. Enterovirus Detection at the Speed of Light. (Poster).

Whiley, DM., Mackay, IM., Siebert, DP., Sloots, TP. (December 2001). Queensland Health and Medical Scientific Meeting. From Research to Diagnosis at the Speed of Light. (Oral).

Sloots, TP., Mackay, IM., Siebert, DP., Nissen, M., (March 2001). Australian Virology Group, Kingfisher Bay, Qld. First Isolations of Human Metapneumovirus in Australia. (Oral).

Mackay, IM., Sloots, TP. (March 2002). CDC Infectious Disease Conference, Atlanta GA, USA. First Isolations of Human Metapneumovirus in Australia. (Oral).

Mackay, IM., Nissen, M., Siebert, DP., Sloots,TP. (April 2002).
Australian Society for Infectious Disease Conference, Barossa Valley,
South Australia. First Isolations Of Human Metapneumovirus In
Australia (Poster).

Nissen, M., Mackay, IM., Siebert, DP., Sloots,TP. (April 2002).
Australian Society for Infectious Disease Conference. Barossa Valley,
South Australia. Epidemiology & clinical features of human
metapneumovirus infection (Oral).

Sloots, TP., Mackay, IM (April 2002). Virology and Serology ASM
Special Interest Group. RBH, Australia. (Oral).

Nissen, M., Mackay, IM., Sloots, TP., (April 2002). Clinical
Features of Human Metapneumovirus Infection. Respiratory
Laboratory, RCH (Oral).

Mackay, IM., Nissen, M., Siebert, DP., Sloots, TP. (July 2002).
Molecular Epidemiology of Human Metapneumovirus in Australian
Children. International Congress of Virology. Paris, France. (Poster).

Nissen, M., Mackay, IM., Siebert, DP., Sloots, TP. (July 2002).
Clinical Features of Human Metapneumovirus Infection in Australian
Children. International Congress of Virology. Paris, France. (Poster).

Mackay, IM., Nissen, M., Siebert, DP., Sloots, TP. (September 2002). Human Metapneumovirus: From Detection to Characterisation. Australian Society of Microbiology Conference. Melbourne, Australia. (Oral).

Nissen, M., Mackay, IM., Siebert, DP., Sloots, TP. (September 2002). Clinical Features of Human Metapneumovirus Infection. Australian Society of Microbiology Conference. Melbourne, Australia. (Oral).

ILLUSTRATIONS.

List of Figures.	Page.
Figure 1.1. Time versus temperature plot during a single PCR cCycle.	5
Figure 1.2. Mechanisms of fluorescence resonance energy transfer (FRET).....	12
Figure 1.3. Kinetic analysis of amplicon accumulation.	19
Figure 1.4. Function of the HybProbes.	22
Figure 1. 5. Function of displacement oligoprobes.	24
Figure 1. 6. Function of the Q-PNA displacement primer.....	25
Figure 1.7. Function of the Light-Up probe.	26
Figure 1. 8. Function of the HyBeacon oligoprobe.....	27
Figure 1.9. Function of the Lightspeed probe.	28
Figure 1.10. Function of the TaqMan oligoprobe.	30
Figure 1.11. Function of the DzyNA Primers.....	33
Figure 1.12. Function of the molecular beacon.....	34
Figure 1.13. Function of the tripartite molecular beacon.....	36
Figure 1.14. Function of the sunrise primer.	38
Figure 1.15. Function of the scorpion primer.	40
Figure 1.16. Function of the LUX primer.....	41
Figure 1.17. Fluorescence melting curve analysis.	56
Figure 1.18. The hMPV genome.	88
Figure 1.19. A schematic of a member of the subfamily <i>Pneumovirinae</i>	94
Figure 2.1. A schematic representation of the generation of LCSN.	123
Figure 2.2. Schematic representation of the construction of LGSN.	124
Figure 2.3. A schematic of the construction of synthetic controls.	128
Figure 2.4. Plasmid maps for wild-type synthetic controls.....	130
Figure 2.5. A schematic representation of the ELAHA process.	158
Figure 3.1. Transgene functional studies.....	171
Figure 3.2. Diagnostic <i>Cftr</i> PCR.....	172
Figure 3.3. Limiting dilution PCR and signal generating units.....	174
Figure 3.4. Sensitivity of the ELAHA versus agarose gel electrophoresis.	178
Figure 3.5. The <i>Gfp</i> and <i>Neo</i> PCR-ELAHA dynamic range.	180
Figure 3.6. Amplicon detection during competitive PCR quantitation.....	182
Figure 3.7. Conventional quantitative competitive PCR.....	184
Figure 3.8. Real-time PCR using SYBR green I.	188
Figure 3.9. FMCA of huGfp dsDNA amplicon.....	190
Figure 3.10. Design of the diagnostic real-time <i>Cftr</i> PCR.	192

Figure 3.11. Quantitative <i>Cftr</i> PCR.	194
Figure 3.12. Efficiency of <i>Cftr</i> quantitation using real-time PCR.	197
Figure 3.13. Efficiency of HybProbe hybridisation.	199
Figure 3.14. FMCA of the <i>Cftr</i> dsDNA amplicon.....	201
Figure 4.1. HSV real-time PCR target.	217
Figure 4.2. Variation in the real-time PCR with magnesium concentrations.....	220
Figure 4.3. HybProbe titration and FMCA.....	224
Figure 4.4. Asymmetric real-time PCR.	226
Figure 4.5. Quantitative HSV PCR.	228
Figure 4.6. Evaluation of HSV FMCA using characterised specimens.	237
Figure 4.7. Misleading melting curve analysis.	239
Figure 4.8. Human enterovirus genome.	243
Figure 4.9. Asymmetric primer concentrations and PCR facilitators.	245
Figure 4.10. HEV nucleotide sequence comparisons.....	248
Figure 4.11. Phylogenetic studies of Queensland HEV strains.	250
Figure 4.12. Assays for the detection of hMPV amplicon.	255
Figure 4.13. Comparison of symmetric and asymmetric hMPV RT-PCR.....	257
Figure 4.14. Schematic representation of the two hMPV RT-PCR assays.....	260
Figure 4.15. Asymmetric hMPV RT-PCR.....	262
Figure 4.16. Dual-round real-time RT-PCR.	264
Figure 4.17. Reversed asymmetric real-time RT-PCR.	266
Figure 4.18. Viral culture studies.	270
Figure 4.19. hMPV growth studies.....	272
Figure 5.1. Viral seroepidemiology.	288
Figure 5.2. Age of hMPV infection.	293
Figure 5.3. Monthly virus infection rates for 2001.....	294
Figure 5.4. Distribution of hMPV positives during 2001 and 2002.....	296
Figure 5.5. Meteorological analysis and hMPV incidence.	298
Figure 5.6. Primer design schemes for the amplification of hMPV genes.....	304
Figure 5.7. Closely related pneumovirus genomes.....	308
Figure 5.8. N gene amplification by RT-PCR.....	310
Figure 5.9. Fractional N gene amino acid similarity.	312
Figure 5.10. N gene amino acid alignment.	313
Figure 5.11. P gene amplification by RT-PCR.	316
Figure 5.12. Fractional P gene amino acid similarity.....	318
Figure 5.13. P gene amino acid alignment.....	320
Figure 5.14. M gene amplification by RT-PCR.....	323
Figure 5.15. Fractional M gene amino acid similarity.....	324
Figure 5.16. M gene amino acid alignment.	325

Figure 5.17. F gene amplification by RT-PCR.	328
Figure 5.18. Fractional F gene amino acid similarity.....	329
Figure 5.19. F gene amino acid alignment and hydropathicity plot.	331
Figure 5.20. Paramyxovirus F gene cleavage sequences.....	335
Figure 5.21. G gene amplification by RT-PCR.	337
Figure 5.22. G gene amplification scheme.	338
Figure 5.23. G gene amino acid alignment.	340
Figure 5.24. G protein hydropathicity.	341
Figure 5.25. L gene amplification by RT-PCR.	343
Figure 5.26. Fractional L gene amino acid similarity.....	344
Figure 5.27. L gene amino acid alignment.	345
Figure 5.28. Diagnostic hMPV amplicons.	351
Figure 5.29. N gene phylogeny.....	352
Figure 5.30. P gene phylogeny.	354
Figure 5.31. M gene phylogeny.....	355
Figure 5.32. F gene phylogeny.	356

List of Tables.

Page.

Table 1.1. Taxonomic structure of the family <i>Paramyxoviridae</i>	85
Table 1.2. F protein cleavage site amino acid sequences.	101
Table 2.1. Listing of all primers used in this thesis.....	150
Table 2.2. Oligonucleotide probes used in this thesis.	153
Table 2.3. Conventional and real-time PCR assay conditions.	159
Table 2.4. Conventional and real-time RT-PCR assay conditions.	160
Table 4.1. Quantitation of HSV in clinical samples	229
Table 4.2. Real-time HSV PCR versus conventional PCR and viral culture.	231
Table 4.3. Comparison of HSV real-time PCR and viral culture.....	234
Table 4.4. Growth characteristics of Australian hMPV strains.....	271
Table 5.1. Distribution of tested specimens during 2001 and 2002.....	291
Table 5.2. hMPV symptomology.....	302
Table 5.3. Strains studied during the gene sequencing studies.	306

TABLE OF CONTENTS

TITLE	I
DECLARATION	III
ABSTRACT	IV
ACKNOWLEDGMENTS	VIII
ABBREVIATIONS	IX
PUBLICATIONS	XI
PRESENTATIONS	XIII
ILLUSTRATIONS	XVII
TABLE OF CONTENTS	XX

CHAPTER 1: LITERATURE REVIEW.

1.1. INTRODUCTION	1
1.2. THE EVOLUTION OF PCR IN VIROLOGY	3
1.3. AMPLICON DETECTION	15
<i>1.3.1. DNA-binding fluorophores</i>	<i>17</i>
<i>1.3.2. Linear oligoprobes</i>	<i>21</i>
<i>1.3.3. 5' Nuclease oligoprobes</i>	<i>28</i>
<i>1.3.4. Hairpin oligoprobes</i>	<i>33</i>
<i>1.3.5. Self-priming fluorogenic amplicon</i>	<i>37</i>
1.4. COMPARISON OF FLUOROGENIC CHEMISTRIES	42
1.5. NOVEL APPLICATIONS OF FLUOROGENIC CHEMISTRIES	42
1.6. VIRAL DETECTION AND QUANTITATION	44
<i>1.6.1. Molecular standards for quantitation</i>	<i>45</i>
<i>1.6.2. Internal control molecules</i>	<i>46</i>
<i>1.6.3. Relative versus absolute quantitation</i>	<i>48</i>
<i>1.6.4. Acquisition of fluorescence data</i>	<i>49</i>
<i>1.6.5. Improved quantitation using real-time PCR</i>	<i>51</i>
1.7. MICROBIAL GENOTYPING	52
1.8. MULTIPLEX REAL-TIME PCR	58
1.9. APPLICATIONS OF REAL-TIME PCR TO VIROLOGY	61

1.10. SYNTHETIC VIRUSES AS MOLECULAR MEDICINES	65
1.10.1. <i>Constructing synthetic viruses</i>	69
1.10.2. <i>Developing a synthetic retrovector</i>	71
1.10.3. <i>Cystic fibrosis: a monogenic gene therapy target.....</i>	74
1.10.4. <i>Monitoring of RCR, provirus and transgene expression</i>	76
1.11. THE FAMILY PARAMYXOVIRIDAE.....	82
1.11.1. <i>Human metapneumovirus</i>	83
1.11.2. <i>Virological characteristics of hMPV.....</i>	85
1.11.3. <i>Pathological response to hMPV infection</i>	90
1.11.4. <i>Genomic organisation of the family Paramyxoviridae.....</i>	93
1.11.5. <i>The subfamily Pneumovirinae: genome and encoded proteins</i>	93
1.11.5.1. <i>The nucleoprotein gene (N) and its encoded protein</i>	95
1.11.5.2. <i>The phosphoprotein gene (P) and its encoded proteins.....</i>	96
1.11.5.3. <i>The matrix genes (M and M2) and their encoded proteins.....</i>	96
1.11.5.4. <i>The polymerase protein ORF (L)</i>	97
1.11.5.5. <i>Non-structural proteins NS1 and NS2</i>	98
1.11.5.6. <i>Envelope glycoproteins.....</i>	98
1.11.5.6.1. <i>The fusion protein ORF (F).....</i>	99
1.11.5.6.2. <i>The small hydrophobic protein (SH) ORF</i>	102
1.11.5.6.3. <i>The attachment glycoprotein ORF (G)</i>	103
1.11.6. <i>Replication and assembly of the family Paramyxoviridae.....</i>	104
1.11.7. <i>Human respiratory syncytial virus</i>	107
1.11.7.1. <i>Host immunity, vaccines and hRSV</i>	109
1.11.7.2. <i>Diagnostic methods to detect hRSV.....</i>	111
1.11.8. <i>Phylogeny and subtypes of the subfamily Pneumovirinae.....</i>	112
1.12. SUMMARY AND CONCLUSIONS.....	114
1.13. AIMS OF THIS PROJECT	120

CHAPTER 2: MATERIALS AND METHODS.

2.1. PLASMIDS.....	121
2.1.1. <i>Synthetic viruses.</i>	121
2.1.2. <i>Synthetic PCR controls.</i>	125
2.1.3. <i>Neo, huGfp, HSV and Cftr wild-type synthetic controls.</i>	125
2.1.4. <i>Neo and huGfp internal synthetic controls.</i>	126
2.1.5. <i>Point mutated Cftr internal synthetic control.</i>	129
2.1.6. <i>Screening and Storage of synthetic controls.</i>	130
2.2. BACTERIAL CULTURES.	131
2.2.1. <i>Bacterial strain and culture conditions.....</i>	131
2.2.2. <i>Bacterial storage and recovery.....</i>	131

2.2.3.	<i>Competent bacteria.</i>	132
2.2.4.	<i>Bacterial transformation.</i>	132
2.2.5.	<i>Small scale plasmid purification.</i>	133
2.2.6.	<i>Large scale plasmid purification.</i>	134
2.3.	DETERMINING THE COPY NUMBER OF SYNTHETIC CONTROLS.	136
2.4.	PATIENT SPECIMENS.	137
2.5.	EUKARYOTIC CELL LINES.	138
2.5.1.	<i>Eukaryotic cell culture.</i>	138
2.5.2.	<i>Eukaryotic cell maintenance.</i>	139
2.5.3.	<i>Eukaryotic cell and culture supernatant storage.</i>	139
2.5.4.	<i>Thawing of eukaryotic cell stocks.</i>	140
2.5.5.	<i>Eukaryotic cell counting.</i>	141
2.5.6.	<i>Eukaryotic cell culture using coverslips.</i>	141
2.5.7.	<i>Transient transfection of eukaryotic cells.</i>	142
2.5.8.	<i>Stable transfection of eukaryotic cells.</i>	143
2.5.9.	<i>Viral transduction of eukaryotic cell</i>	144
2.5.10.	<i>Viral isolation by culture.</i>	144
2.5.11.	<i>Detection of β-galactosidase.</i>	145
2.6.	FLUORESCENCE STUDIES.	146
2.6.1.	<i>Transgene fluorescence.</i>	146
2.6.2.	<i>Immunofluorescent assays.</i>	146
2.7.	THE POLYMERASE CHAIN REACTION.	148
2.7.1.	<i>Presentation of PCR data.</i>	148
2.7.2.	<i>Oligonucleotide primer design strategy.</i>	149
2.7.3.	<i>Conventional PCR.</i>	154
2.7.4.	<i>Conventional RT-PCR.</i>	155
2.7.5.	<i>Analytical agarose gel electrophoresis.</i>	155
2.7.6.	<i>Enzyme linked amplicon hybridisation assay.</i>	156
2.7.7.	<i>Real-time PCR using the LightCycler.</i>	161
2.7.8.	<i>Real-time RT-PCR using the LightCycler.</i>	162
2.8.	FLORESCENCE MELTING CURVE ANALYSIS.	163
2.9.	NUCLEOTIDE SEQUENCING AND SEQUENCE ANALYSES.	163

CHAPTER 3: QUANTIFYING SYNTHETIC VIRUSES.

3.1.	INTRODUCTION.	168
3.2.	AIM.	168
3.3.	RESULTS.	169
3.3.1.	<i>Retrovector transfection and transduction.</i>	169
3.3.1.1.	<i>Detection of transgene function.</i>	170
3.3.2.	<i>Preparation of synthetic PCR controls.</i>	173
3.3.3.	<i>Conventional amplification and detection of huGfp and Neo.</i>	175
3.3.4.	<i>ELAHA versus agarose gel electrophoresis.</i>	177

3.3.5.	<i>The kinetics of the Neo and huGfp PCR-ELAHA system.</i>	179
3.3.6.	<i>Amplicon dilutions for competitive quantitative PCR.</i>	181
3.3.7.	<i>Quantifying proviral DNA using competitive PCR.</i>	183
3.3.8.	<i>The development of real-time PCR to detect transgenes.</i>	187
3.3.8.1.	<i>Use of the SYBR Green I non-specific chemistry to detect huGfp.</i>	187
3.3.8.2.	<i>Use of a pair of linear hybridisation probes to detect Cftr amplicon.</i>	191
3.3.8.3.	<i>Quantitation of Cftr using HybProbes.</i>	193
3.3.8.4.	<i>FMCA for the discrimination of co-amplified template using HybProbes.</i>	197
3.4.	DISCUSSION.	203
3.4.1.	<i>Creating a model for synthetic PCR control development.</i>	203
3.4.2.	<i>Detecting and quantifying synthetic viruses.</i>	204
3.4.3.	<i>Non-specific fluorogenic chemistry: SYBR green I real-time PCR.</i>	208
3.4.4.	<i>Specific fluorogenic chemistry: oligoprobe real-time PCR.</i>	209
3.5.	CONCLUSION.	212

CHAPTER 4: DEVELOPMENT OF REAL-TIME PCR ASSAYS TO DETECT CHARACTERISED AND EMERGING VIRUSES.

4.1.	INTRODUCTION.	214
4.2.	AIM.	215
4.3.	RESULTS.	215
4.3.1.	<i>Herpes simplex virus (HSV).</i>	215
4.3.2.	<i>Optimisation of the HSV real-time PCR assay.</i>	219
4.3.3.	<i>Quantitation using the HSV real-time PCR.</i>	227
4.3.4.	<i>Validation of the HSV real-time PCR using characterised specimens.</i>	230
4.3.5.	<i>Typing of herpes simplex viruses by real-time PCR.</i>	236
4.4.	HUMAN ENTEROVIRUSES 71 (EV71).	241
4.4.1.	<i>Optimisation of the real-time RT-PCR screening assay.</i>	243
4.4.2.	<i>Enterovirus 71-specific assay.</i>	246
4.4.3.	<i>Nucleotide sequencing of the EV71 assay products.</i>	247
4.4.4.	<i>Phylogenetic analysis of EV71-like amplicon.</i>	249
4.5.	HUMAN METAPNEUMOVIRUS.	252
4.5.1.	<i>Oligonucleotide specificity of the hMPV RT-PCR.</i>	253
4.5.2.	<i>Relative sensitivity of the hMPV RT-PCR-ELAHA.</i>	254
4.5.3.	<i>Asymmetric versus symmetric PCR.</i>	256
4.5.4.	<i>Development of an hMPV Real-Time RT-PCR.</i>	257
4.5.5.	<i>Comparative evaluation of the hMPV RT-PCR assays.</i>	267
4.5.6.	<i>Sequencing of the hMPV amplicon.</i>	268
4.5.7.	<i>Confirmation of active hMPV infection.</i>	268

4.6. DISCUSSION.....	275
4.6.1. <i>Herpes simplex virus (HSV)</i>	277
4.6.2. <i>Human enteroviruses 71 (EV71)</i>	279
4.6.3. <i>Asymmetric real-time PCR</i>	280
4.6.4. <i>Human metapneumovirus</i>	281
4.7. CONCLUSIONS	283

CHAPTER 5: CHARACTERISTION OF AN AUSTRALIAN METAPNEUMOVIRUS.

5.1. INTRODUCTION.	286
5.2. AIM.....	287
5.3. HMPV SEROEPIDEMIOLOGY WITHIN AN AUSTRALIAN POPULATION.....	287
5.4. EPIDEMIOLOGY OF HMPV.	290
5.5. INFLUENCE OF METEOROLOGY ON HMPV INFECTION.	297
5.6. CLINICAL IMPLICATIONS OF HMPV INFECTION DURING 2001.....	300
5.7. PRIMER DESIGN AND NUCLEOTIDE SEQUENCING STRATEGIES.	303
5.7.1. <i>The hMPV nucleoprotein (N) gene</i>	309
5.7.2. <i>The hMPV phosphoprotein (P) gene</i>	315
5.7.3. <i>The hMPV matrix (M) gene</i>	322
5.7.4. <i>The hMPV fusion (F) gene</i>	327
5.7.5. <i>The hMPV attachment (G) gene</i>	336
5.7.6. <i>The hMPV large (L) gene</i>	342
5.8. SUBTYPING OF HMPV.....	347
5.9. DISCUSSION.....	357
5.9.1. <i>Viral epidemiology</i>	358
5.9.2. <i>Clinical implications of infection with hMPV</i>	361
5.9.3. <i>Nucleotide sequencing studies of Australian hMPV</i>	361
5.9.4. <i>Subtyping of hMPV</i>	363
5.10. CONCLUSION.	364

CHAPTER 6: GENERAL DISCUSSION AND CONCLUSIONS.

6.1. INTRODUCTION.	366
6.2. OLIGOPROBE-ENHANCED SPECIFICITY.	369
6.3. REAL-TIME PCR.....	376
6.4. CHARACTERISATION OF AN EMERGING PARAMYXOVIRUS.	381

6.5. CONCLUSIONS.	387
6.6. FUTURE DIRECTIONS.	390
6.7. FINAL OUTCOMES.	395

CHAPTER 7. BIBLIOGRAPHY

.....	396
--------------	------------